Credit Suisse Ag Lipocine Inc. Transaction History

Credit Suisse Ag

  • $101 Billion
  • Q1 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 12, 2021
SELL
$1.2 - $1.69 $14,401 - $20,281
-12,001 Closed
0 $0
Q3 2020

Nov 13, 2020
BUY
$1.21 - $2.23 $14,521 - $26,762
12,001 New
12,001 $17,000
Q3 2017

Nov 14, 2017
SELL
$3.67 - $4.19 $116,280 - $132,755
-31,684 Closed
0 $0
Q2 2017

Aug 14, 2017
BUY
N/A
31,684
31,684 $127,000

About Lipocine Inc.

LPCN Quotes by TradingView
  • Ticker LPCN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,510,800
  • Market Cap $434M
  • Description
  • Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...
More about LPCN
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email